Shopping Cart 0
Cart Subtotal
USD 0

Amicus Therapeutics Inc (FOLD) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Amicus Therapeutics Inc (FOLD)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Amicus Therapeutics Inc (Amicus Therapeutics) is a biotechnology company that focuses on the research, development and commercialization of small molecules drugs and orally administered drugs known as pharmacological chaperones for the treatment of rare and orphan diseases. The company's lead product, Migalastat HCl, a small molecule is used for the treatment of Fabry disease. The other development products in the pipeline include ATB200 for the treatment of pompe disease; SD-101 for Epidermolysis Bullosa (EB), chronic, rare connective tissue disorder; and enzyme replacement therapies for other rare diseases. It has presence in the US, the UK, Ireland, France, the Netherlands, Germany, Spain, Italy and Japan. Amicus Therapeutics is headquartered in Cranbury, New Jersey, the US.

Amicus Therapeutics Inc Key Recent Developments

Jun 08,2018: Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors

May 08,2018: Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates

Feb 28,2018: Amicus Therapeutics Announces Full-Year 2017 Financial Results and 2018 Corporate Updates

Feb 27,2018: Amicus Therapeutics Launches Healing Beyond Disease Initiatives to Change People's Lives Living with Rare Diseases

Jan 08,2018: Amicus Therapeutics Provides Full-Year 2018 Strategic Outlook and Financial Guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Amicus Therapeutics Inc-Key Facts 6

Amicus Therapeutics Inc-Key Employees 7

Amicus Therapeutics Inc-Key Employee Biographies 8

Amicus Therapeutics Inc-Major Products and Services 10

Amicus Therapeutics Inc-History 11

Amicus Therapeutics Inc-Company Statement 13

Amicus Therapeutics Inc-Locations And Subsidiaries 14

Head Office 14

Other Locations & Subsidiaries 14

Section 2-Company Analysis 16

Company Overview 16

Amicus Therapeutics Inc-Business Description 17

Amicus Therapeutics Inc-Corporate Strategy 18

Amicus Therapeutics Inc-SWOT Analysis 19

SWOT Analysis-Overview 19

Amicus Therapeutics Inc-Strengths 19

Amicus Therapeutics Inc-Weaknesses 20

Amicus Therapeutics Inc-Opportunities 21

Amicus Therapeutics Inc-Threats 22

Amicus Therapeutics Inc-Key Competitors 23

Section 3-Company Financial Ratios 24

Financial Ratios-Capital Market Ratios 24

Financial Ratios-Annual Ratios 25

Performance Chart 27

Financial Performance 27

Financial Ratios-Interim Ratios 28

Financial Ratios-Ratio Charts 29

Section 4-Company's Lifesciences Financial Deals and Alliances 30

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31

Amicus Therapeutics Inc, Recent Deals Summary 32

Section 5-Company's Recent Developments 33

Jun 08, 2018: Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors 33

May 08, 2018: Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates 34

Feb 28, 2018: Amicus Therapeutics Announces Full-Year 2017 Financial Results and 2018 Corporate Updates 36

Feb 27, 2018: Amicus Therapeutics Launches Healing Beyond Disease Initiatives to Change People's Lives Living with Rare Diseases 38

Jan 08, 2018: Amicus Therapeutics Provides Full-Year 2018 Strategic Outlook and Financial Guidance 39

Nov 08, 2017: Amicus Therapeutics Announces Third Quarter 2017 Financial Results and Corporate Updates 41

Oct 06, 2017: Amicus Therapeutics Appoints Michael C. Diem, MD as Senior Vice President of Business and Corporate Development 44

Aug 07, 2017: Amicus Therapeutics Announces Second Quarter 2017 Financial Results and Corporate Updates 45

May 09, 2017: Amicus Therapeutics Announces First Quarter 2017 Financial Results and Corporate Updates 47

Mar 01, 2017: Amicus Therapeutics Announces Full-Year 2016 Financial Results and Corporate Updates 49

Section 6-Appendix 51

Methodology 51

Ratio Definitions 51

About GlobalData 55

Contact Us 55

Disclaimer 55


List Of Figure

List of Figures

Amicus Therapeutics Inc, Performance Chart (2013-2017) 27

Amicus Therapeutics Inc, Ratio Charts 29

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 31


List Of Table

List of Tables

Amicus Therapeutics Inc, Key Facts 6

Amicus Therapeutics Inc, Key Employees 7

Amicus Therapeutics Inc, Key Employee Biographies 8

Amicus Therapeutics Inc, Major Products and Services 10

Amicus Therapeutics Inc, History 11

Amicus Therapeutics Inc, Other Locations 14

Amicus Therapeutics Inc, Subsidiaries 14

Amicus Therapeutics Inc, Key Competitors 23

Amicus Therapeutics Inc, Ratios based on current share price 24

Amicus Therapeutics Inc, Annual Ratios 25

Amicus Therapeutics Inc, Annual Ratios (Cont...1) 26

Amicus Therapeutics Inc, Interim Ratios 28

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 30

Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 31

Amicus Therapeutics Inc, Recent Deals Summary 32

Currency Codes 51

Capital Market Ratios 51

Equity Ratios 52

Profitability Ratios 52

Cost Ratios 53

Liquidity Ratios 53

Leverage Ratios 54

Efficiency Ratios 54

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Amicus Therapeutics Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Shire Plc

Sanofi-Aventis AB

RegeneRx Biopharmaceuticals Inc

Protalix BioTherapeutics Inc

Intercytex Ltd

InMed Pharmaceuticals Inc

Fibrocell Science Inc

BioMarin Pharmaceutical Inc